Meeting
2013 Gastrointestinal Cancers Symposium
Randomized phase III trial of irinotecan plus cisplatin versus irinotecan alone after S-1 based chemotherapy failure for patients with advanced and recurrent gastric cancer (AGC) (TCOG GI-0801).
Authors
Ken Shimada
The Tokyo Cooperative Oncology Group
Ken Shimada , Katsuhiko Higuchi , Naoshi Hosaka , Eisaku Sasaki , Norisuke Nakayama , Kenji Amagai , Yuiti Takeda , Toshikazu Moriwaki , Takashi Sekikawa , Kazuhito Yajima , Satoshi Tanabe , Yusuke Saito , Yoshiharu Maeda , Ken Nishimura , Tohru Sasaki , Kouji Kobayashi , Tatsu Shimoyama , Ichinosuke Hyodo , Wasaburo Koizumi , Toshikazu Sakuyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000001028
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr61)
DOI
10.1200/jco.2013.31.4_suppl.61
Abstract #
61
Poster Bd #
B5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.
First Author: Zev A. Wainberg
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
First Author: Hironaga Satake
Poster
2018 ASCO Annual Meeting
An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).
First Author: Daisuke Sakai
Poster
2013 Gastrointestinal Cancers Symposium
Efficacy analyses of a randomized phase III clinical trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in patients with advanced or recurrent gastric cancer refractory to prior S-1 chemotherapy.
First Author: Hitoshi Inagaki